4. Olson B, Mallow C, Reilly C, et al. Neoadjuvant SEMA4D blockade with nivolumab alters suppressive myeloid
cells while elevating B cell and CD26hi T cell infiltration in the tumors of patients with resectable stage III melanoma. Journal for ImmunoTherapy of Cancer 2022;10: doi: 10.1136/jitc-2022-SITC2022.0613
About Pepinemab
Pepinemab is a humanized IgG4 monoclonal
antibody designed to block SEMA4D, which can trigger collapse of the actin cytoskeleton and loss of homeostatic functions of astrocytes and glial cells in the brain and dendritic cells in immune tissue. Pepinemab has been administered to more than
400 patients and appears to be well-tolerated and to have a favorable safety profile.
About Vaccinex Inc.
Vaccinex, Inc. is pioneering a differentiated approach to treating slowly progressive neurodegenerative diseases and cancer through the inhibition of
semaphorin 4D (SEMA4D). The Companys lead drug candidate, pepinemab, is designed to block SEMA4D, a potent biological effector that is believed to trigger damaging inflammation in chronic diseases of the brain and inhibit immune infiltration
and activation in tumors. In neurodegenerative diseases, pepinemab is being studied as a monotherapy in the Phase 1/2a SIGNAL-AD study in Alzheimers Disease, with ongoing exploration of potential
Phase 3 development in Huntingtons disease. In oncology, pepinemab is being evaluated in combination with KEYTRUDA® in the Phase 1b/2
KEYNOTE-B84 study in recurrent or metastatic head and neck cancer (HNSCC) and in combination with BAVENCIO® in a Phase 1b/2 study in
patients with metastatic pancreatic adenocarcinoma (PDAC). The oncology clinical program also includes several investigator-sponsored studies in solid tumors including breast cancer and melanoma.
Forward Looking Statements
To the extent that statements
contained in this presentation are not descriptions of historical facts regarding Vaccinex, Inc. (Vaccinex, we, us, or our), they are forward-looking statements reflecting managements
current beliefs and expectations. Such statements include, but are not limited to, statements about our plans, expectations and objectives with respect to the results and timing of the SIGNAL-AD clinical
trial; the direct or indirect effect the SIGNAL-AD clinical trial will have on our financial resources available for our innovative initiatives; expectations and objectives with respect to the results and
timing of the KEYNOTE-B84 clinical trial, the use and potential benefits of pepinemab in neurodegenerative diseases like AD and HD, and cancer; our plans, expectations and objectives with respect to the
results and timing of a trial of treatment with pepinemab and KEYTRUDA in combination with chemotherapy in R/M HNSCC, lung cancer, metastatic PDAC and other indications, the potential for benefits as compared to single agent KEYTRUDA® or BAVENCIO®, expectations with respect to the collaboration of Merck, the expected timeline for disclosure of trial results at scientific
conferences or through publications, and other statements identified by words such as anticipate, believes, hope, being, may, will, appears, expect,
continue, ongoing, potential, possibly, prevents, suggest, and similar expressions or their negatives (as well as other words and expressions referencing future events,
conditions, or circumstances). Forward-looking statements involve substantial risks and uncertainties that could cause the outcome of our research and pre-clinical development programs, clinical development
programs, future results, performance, or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, uncertainties inherent in the execution, cost and
completion of preclinical studies and clinical trials, that interim and preliminary data may not be predictive of final results and does not ensure success in later clinical trials,